Courts Weigh Thousands of GLP-1 Injury Claims as Regulators Confront a Data Gap

What Happened

Two consolidated federal proceedings over alleged GLP-1 drug injuries are moving forward, and the central scientific question remains unresolved: how often do medicines like Ozempic, Wegovy, Mounjaro, and Zepbound actually cause serious, life-altering harm?

Court filings describe a plaintiff population that includes 247 people diagnosed with NAION — a form of optic neuropathy in which tiny strokes cut blood flow to the optic nerve, causing permanent, inoperable vision loss — alongside more than 4,000 plaintiffs alleging serious digestive injuries such as pancreatitis and gallstones. A lead court-appointed attorney for the plaintiffs argues that stronger warnings "would have made a difference in the lives of real people."

The manufacturers dispute the claims. Novo Nordisk, maker of Ozempic and Wegovy, says the cases lack merit and points to subsequent research casting doubt on a causal link to NAION. Eli Lilly, maker of Mounjaro and Zepbound, says it will "vigorously defend" the claims.

Who Is Affected

The stakes are unusually broad. Survey analysis suggests more than one in 10 Americans currently take a GLP-1, and roughly one in seven have used one at some point. Prescriptions keep expanding across conditions, while the alleged injuries — sudden blindness, pancreatitis, gallstones — are severe and life-changing.

Patients who obtained GLP-1s through loosely supervised online sellers face a second problem: side effects from gray-market products often go unreported entirely, leaving poison-control centers as the only witnesses.

Timeline

• 2023: Research in a major ophthalmology journal reports higher NAION rates among diabetic patients taking semaglutide. Two professional eye-care societies respond that the study design shows correlation, not causation, and advise patients not to stop their prescriptions on that basis.
• Since 2024: The FDA's voluntary adverse-event database logs more than 1,000 optic-nerve reports and 1,928 pancreatitis reports — including 135 cases of necrotizing pancreatitis — out of nearly 190,000 total GLP-1 reports, most describing minor issues like digestive upset or injection-site redness.
• 2026: The consolidated multi-district proceedings advance with thousands of plaintiffs. The FDA confirms its own NAION study is underway and that it will "determine the need for regulatory action" once complete. European regulators have already classified NAION as a "very rare" semaglutide side effect and updated prescribing information.

What This Means for Researchers

The core problem is evidence quality. Voluntary reporting both undercounts and distorts. One diabetes specialist acknowledged treating three patients who developed pancreatitis or gallstones while on GLP-1s without reporting any of them, because he could not exclude preexisting disease.

Clinical trials are structurally incapable of detecting very rare events across a diverse real-world population, and the post-market databases meant to fill that gap are incomplete by design. Until better pharmacoepidemiology exists, both courts and regulators are being asked to decide causation questions that the current evidence cannot cleanly answer.

How to Verify Your Peptides

If you use compounded or gray-market GLP-1 products, laboratory verification is the only meaningful safeguard against contamination, mislabeling, and potency errors:

• Learn how independent testing works
• Compare HPLC and LC-MS testing methods
• Check the basics of identity, purity, and fill weight

Safe Alternatives

Serious adverse-event signals are one more reason to avoid unverified sellers entirely. Review our GLP-1 peptide profiles, including semaglutide, and see which suppliers hold verifiable quality records in our vendor directory.

Sources

• Regulatory announcements and adverse-event database analyses, 2023-2026
• Peer-reviewed ophthalmology and endocrinology research
• Industry reports on consolidated litigation filings